Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD151 molecule (Raph blood group) (CD151)
- Target
- CD151
- Molecular classification
- Tetraspanin (transmembrane 4 superfamily), Cell-surface glycoprotein, Membrane protein
01
Overview
CD151 molecule (Raph blood group), commonly abbreviated as CD151, is a tetraspanin family cell surface glycoprotein that organizes membrane protein complexes by binding integrins and other tetraspanins. It plays a key role in processes such as cell adhesion, migration, and proliferation through signal transduction and modulation of integrin function. CD151 has pathogenic roles in cancer metastasis, respiratory disease, and certain immunological and genetic disorders. Its wide tissue expression and involvement in cellular signaling make it both a biomarker and a promising therapeutic target, though its essential role in normal tissue homeostasis presents notable safety and specificity challenges.
- Other names
- CD151TSPAN24Platelet-endothelial tetraspan antigen 3 (PETA-3)SFA-1GP27Membrane glycoprotein SFA-1Platelet surface glycoprotein gp27Tetraspanin-24RAPHEBS7MER2Raph blood group antigenHemidesmosomal tetraspanin CD151
02
Mechanism of action
Inhibition/antagonism of integrin-CD151 interactions (to block cell migration/metastasis) Antibody-based inhibitors to disrupt CD151 function or cell surface expression Modulation of immune activation (potential immunotherapeutic application)
03
Biological functions
Cell adhesionCell migration/motilityCell proliferationSignal transductionImmune cell activation (T-cell activation)Integrin trafficking and regulationBasement membrane assemblyTumor initiation and metastasis
04
Disease associations
Cancer (tumor progression, metastasis)Respiratory diseases (asthma, influenza, idiopathic pulmonary fibrosis)Epidermolysis bullosa (skin fragility disorder)Immunological disorders (T-cell activation marker)Cardiovascular disease (platelet function)
05
Safety considerations
Potential off-target effects due to ubiquitous expression in normal tissues, raising concerns for adverse events in immune modulation, wound healing, and homeostasisPlatelet aggregation or vascular complications from targeting CD151Risk of immune dysregulation
06
Interacting drugs
No approved drugs directly target CD151 as of 2024; however, investigational agents targeting tetraspanins, and CD151-inhibiting antibodies, are in preclinical or early clinical development for cancer and fibrosis
07
Biomarkers
CD151 expression as a marker for T-cell activationCD151 protein levels as a prognostic marker in lung cancer and asthmaCD151 as a screening or prognostic tool in fibrosis and other cancers
Beyond the preview
Go deeper on CD151 molecule (Raph blood group) (CD151).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD151 molecule (Raph blood group) (CD151).